ClinicalTrials.gov
ClinicalTrials.gov Menu

RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01709019
Recruitment Status : Completed
First Posted : October 17, 2012
Last Update Posted : March 5, 2014
Sponsor:
Information provided by (Responsible Party):
Novavax

October 15, 2012
October 17, 2012
March 5, 2014
October 2012
July 2013   (Final data collection date for primary outcome measure)
  • Assessment of Safety [ Time Frame: Day 0 to Day 364 ]

    Number (and percentage) of subjects with solicited local and systemic Adverse Events over the seven days post injection; all adverse events, solicited and unsolicited over 56 days post-first injection.

    Significant New Medical Conditions, Medically Attended Events and Serious Adverse Events will be collected for one year.

  • Immunogenicity as assessed by serum IgG antibody titers for the F-Protein antigen [ Time Frame: Day 0 to Day 364 ]

    Immunogenicity will be measured using derived / calculated endpoints based on:

    • Geometric mean titer (GMT)
    • Geometric mean ratio (GMR)
    • Seroconversion rate (SCR)
    • Seroresponse rate (SRR)
Same as current
Complete list of historical versions of study NCT01709019 on ClinicalTrials.gov Archive Site
Immunogenicity as assessed by serum HAI titers specific for the influenza antigens contained in the seasonal vaccine. [ Time Frame: Day 0 to Day 56 ]

Immunogenicity will be measured using derived / calculated endpoints based on:

  • Geometric mean titer (GMT)
  • Geometric mean ratio (GMR)
  • Seroconversion rate (SCR)
  • Seroprotection rate (SPR)
Same as current
Not Provided
Not Provided
 
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.

Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be replaced. Randomization will be stratified by age (60 to <75 years and ≥ 75 years) in order to distribute the proportion of such persons in each age group equally across treatment groups.

Treatments will comprise a single IM dose of a placebo or RSV-F protein nanoparticle vaccine on Day 0, with concurrent IM immunization with a licensed inactivated influenza vaccine. A rescue dose of the licensed TIV will be provided to subjects in all groups except the placebo group on Day 28, the placebo group will receive saline. For each subject, study follow-up will span approximately one year from the first immunization (on Day 0) for all subjects.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Respiratory Syncytial Virus (RSV)
  • Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    0.5mL IM injections
  • Biological: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
    0.5mL IM injections
  • Biological: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    0.5mL IM injections
  • Biological: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    0.5mL IM injections
  • Biological: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
    0.5mL IM Injections
  • Experimental: Group A
    Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    Intervention: Biological: Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
  • Experimental: Group B
    Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    Intervention: Biological: Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)
  • Experimental: Group C
    High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    Intervention: Biological: High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
  • Experimental: Group D
    High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
    Intervention: Biological: High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)
  • Placebo Comparator: Group E
    Placebo (Day 0 & Day 28); Seasonal TIV (Day 28)
    Intervention: Biological: Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
Fries L, Shinde V, Stoddard JJ, Thomas DN, Kpamegan E, Lu H, Smith G, Hickman SP, Piedra P, Glenn GM. Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults. Immun Ageing. 2017 Apr 12;14:8. doi: 10.1186/s12979-017-0090-7. eCollection 2017.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
220
Same as current
March 2014
July 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult males and females, ≥ 60 years of age, without symptomatic cardiopulmonary disease. Note that subjects who have any functional limitation or symptoms related to cardiac and/or pulmonary disease (including asthma or other episodic symptoms), or who receive ongoing therapy to control symptoms or functional limitation, are not eligible. The following are examples of subjects who may bear cardio-pulmonary diagnoses but who would remain eligible:

    1. Subjects on stable (no change in ≥ 2 months) therapy for findings (e.g., hypertension or hyperlipidemia) that are not associated with current symptoms or disability.
    2. Subjects who receive intermittent prophylaxis for risks associated with asymptomatic findings (e.g., antibiotic prophylaxis prior to dental procedures in a subject with asymptomatic mitral valve prolapse).
    3. Other clinically insignificant findings, not deemed to be associated with increased risk due to respiratory viral infections as determined by the Investigator.
  • Free of other illnesses which are believed to increase the risk of influenza or influenza related complications including: diabetes mellitus, congenital or acquired blood dyscrasias, renal or hepatic dysfunction, and morbid obesity.
  • Willing and able to give informed consent prior to study enrollment.
  • Able to comply with study requirements.

Exclusion Criteria:

  • Participation in research involving investigational product (drug / biologic / device) within 45 days before planned date of first vaccination and/or planned participation at any time during the study.
  • History of a serious reaction to any prior vaccination or known allergy to constituents of licensed TIV (e.g., egg proteins).
  • History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine.
  • Receipt of any influenza vaccine within the preceding 3 months.
  • Receipt of any vaccine in the 4 weeks preceding the study vaccination and planned receipt of a licensed vaccine any time prior to Day 56.
  • Receipt of an RSV vaccine at any time.
  • Any known or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination.
  • Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted provided these are not administered for diagnoses inconsistent with the inclusion criteria. The use of inhaled glucocorticoids, although typically not associated with system absorption, will generally indicate the presence of a diagnosis inconsistent with inclusion criteria 1 or 2.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
  • Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration).
  • Known disturbance of coagulation.
  • Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
  • Any condition that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
Sexes Eligible for Study: All
60 Years and older   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01709019
NVX757.102
No
Not Provided
Not Provided
Novavax
Novavax
Not Provided
Study Director: D. Nigel Thomas, Ph.D. Novavax, Inc.
Novavax
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP